此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Post-market Prospective Clinical Study of Eurosilicone Luna Mammary Implants

2026年7月1日 更新者:GCA (Eurosilicone)

A Prospective, Multi-centre, Observational, Non-comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Eurosilicone LunaXT Range of Silicone Breast Implants When Used in Breast Implantation.

The goal of this observational, non-comparative study is to determine the frequency and rate of rupture and capsular contracture Baker III-IV of Eurosilicone Luna range of breast implants, over a 10-year period following surgical implantation in female population between 18 and 65 years old undergoing primary or revision of breast augmentation or breast reconstruction.

研究概览

研究类型

观察性的

注册 (估计的)

650

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Patients from centers participating to the study.

描述

Inclusion Criteria:

  • The target population includes subjects undergoing augmentation or reconstructive breast implant surgery in which the Eurosilicone Luna mammary implant is recommended.

Inclusion criteria are:

  1. Genetic female subjects aged between 18 and 65 years old.
  2. Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:

i. Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs (synthetic or natural).

ii. Primary breast augmentation (cosmetic surgery) with or without mastopexy iii. Breast revision surgery with or without mastopexy c) Subjects who have received a Eurosilicone Luna implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow-up appointments as per the study protocol.

Exclusion criteria are:

  1. Subjects with a BMI >35.
  2. Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
  3. Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer-related clinical studies.
  4. Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
  5. Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
  6. Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
  7. Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
  8. Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
  9. Subjects with a known history of compromised wound healing.
  10. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
  11. Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants.
  12. Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Aesthetic indications
Primary or revision breast augmentation with or without mastopexy.
The procedure is carried out at the surgeon's discretion. This includes the incision location, the implant placement, the intraoperative applications.
其他名称:
  • Cosmetic breast implant surgery
  • Aesthetic breast implant surgery
Medical indications
Primary or revision of breast reconstruction. Immediate or delayed reconstruction. With or without associated chemotherapy and/or radiotherapy.
The procedure is carried out at the surgeon's discretion. This includes the incision location, the implant placement, the intraoperative applications.
其他名称:
  • 即刻乳房再造
  • Delayed breast reconstruction

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Frequency and rate of implant rupture
大体时间:10 years
10 years
Frequency and rate of capsular contracture Baker III-IV
大体时间:10 years
10 years

次要结果测量

结果测量
措施说明
大体时间
Rate of the secondary surgical procedures required for correction of complications
大体时间:10 years
10 years
Patient satisfaction
大体时间:10 years
This will be determined using a questionnaire assessing the qualify of life.
10 years
Rate and frequency of local complications
大体时间:10 years

These complications may be related to the device itself or to the surgical procedure:

  • Capsular contracture of Baker Grade I-II
  • Haematoma
  • Rupture
  • Seroma
  • Severe and continuing pain
  • Post-operative infection
  • Explantation as a result of infection
  • Implant displacement/extrusion
  • Implant misplacement/malrotation
  • Wrinkling/folds
  • Breast Implant Associate Anaplastic Large Cell Lymphoma
  • Breast Implant Ilness (BII)/ Autoimmune/Autoinflammatory Syndrome Induced by Adjuvants (Asia)
  • Delayed or abnormal wound healing occurring within the first 3 months of surgery
  • Any other complications considered by the Investigator to be related to the device or surgical procedure
10 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年3月30日

初级完成 (估计的)

2038年12月31日

研究完成 (估计的)

2038年12月31日

研究注册日期

首次提交

2026年6月25日

首先提交符合 QC 标准的

2026年6月25日

首次发布 (实际的)

2026年7月1日

研究记录更新

最后更新发布 (实际的)

2026年7月6日

上次提交的符合 QC 标准的更新

2026年7月1日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • CLA-0007

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅